Bernard Zinman

Last updated

Bernard Zinman is a Canadian clinical and research endocrinologist, whose research at the University of Toronto focuses on type 1 and type 2 diabetes. He directed the Mount Sinai Hospital Leadership Sinai Centre for Diabetes and the Banting and Best Diabetes Centre (university of Toronto). In 2019, he was appointed as an Officer to the Order of Canada in recognition of his scientific contributions, including the development of preventative therapies for diabetes.

Contents

Early life and education

Zinman was born in Montreal. [1] [2] He completed his medical degree at McGill University, with further training in internal medicine and endocrinology at McGill University and the University of Toronto. [3]

Career

Zinman joined Mount Sinai Hospital in 1990. [1] His research has focused on the treatment of diabetes. [4] He directed the Banting and Best Diabetes Centre at the University of Toronto from 1993 to 2000. [5] During this time Zinman worked with Robert Hegele and Stewart Harris to identify the first diabetes-risk gene in an aboriginal population. [6]

In 2000 Zinman became Director of the Leadership Sinai Centre for Diabetes, an Ontario diabetes research clinic [7] and Zinman is currently a professor of medicine at the University of Toronto and a Senior Scientist at Mount Sinai's Lunenfeld-Tanenbaum Research Institute. [1]

Zinman was one of three Canadian principal investigators leading the U.S.-Canada Diabetes Control and Complications Trial (DCCT), [1] [2] [8] which was launched in 1982 across 29 hospitals and universities; this large type 1 diabetes complications study set out to determine whether intensive or conventional treatment was more effective in tackling diabetic complications. [8] The DCCT provided evidence showing that maintaining blood glucose levels close to normal slows the onset and progression of diabetic complications, such as those found in the eye, kidneys, and nervous system. [8] [9] [10] Later on, in a long-term clinical trial consisting of over 7,000 adults in 42 countries with type 2 diabetes, Zinman demonstrated that empagliflozin treatment reduced the risk of death caused by cardiovascular disease by 38 percent. [11] [12]

Zinman is a Judy Pencer Family Chair in Diabetes Research, and was appointed as an Officer to the Order of Canada in 2019. [13] [14] [15] He was the 2020 recipient of the American Diabetes Association's Outstanding Achievement in Clinical Diabetes Research Award. [16] Zinman is also one of the Sinai 100 Chairs, funded by the Sinai Health Foundation. [2]

Personal life

Zinman is married, and has three children and four grandchildren. [1]

Selected bibliography

See also

Related Research Articles

<span class="mw-page-title-main">Frederick Banting</span> Canadian medical scientist and doctor

Sir Frederick Grant Banting was a Canadian medical scientist, physician, painter, and Nobel laureate noted as the co-discoverer of insulin and its therapeutic potential.

<span class="mw-page-title-main">Hyperglycemia</span> Too much blood sugar, usually because of diabetes

Hyperglycemia is a condition in which an excessive amount of glucose circulates in the blood plasma. This is generally a blood sugar level higher than 11.1 mmol/L (200 mg/dL), but symptoms may not start to become noticeable until even higher values such as 13.9–16.7 mmol/L (~250–300 mg/dL). A subject with a consistent fasting blood glucose range between ~5.6 and ~7 mmol/L is considered slightly hyperglycemic, and above 7 mmol/L is generally held to have diabetes. For diabetics, glucose levels that are considered to be too hyperglycemic can vary from person to person, mainly due to the person's renal threshold of glucose and overall glucose tolerance. On average, however, chronic levels above 10–12 mmol/L (180–216 mg/dL) can produce noticeable organ damage over time.

<span class="mw-page-title-main">Type 2 diabetes</span> Type of diabetes mellitus with high blood sugar and insulin resistance

Type 2 diabetes (T2D), formerly known as adult-onset diabetes, is a form of diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. Common symptoms include increased thirst, frequent urination, fatigue and unexplained weight loss. Symptoms may also include increased hunger, having a sensation of pins and needles, and sores (wounds) that do not heal. Often symptoms come on slowly. Long-term complications from high blood sugar include heart disease, strokes, diabetic retinopathy which can result in blindness, kidney failure, and poor blood flow in the limbs which may lead to amputations. The sudden onset of hyperosmolar hyperglycemic state may occur; however, ketoacidosis is uncommon.

Glycated hemoglobin is a form of hemoglobin (Hb) that is chemically linked to a sugar. Most monosaccharides, including glucose, galactose and fructose, spontaneously bond with hemoglobin when present in the bloodstream. However, glucose is only 21% as likely to do so as galactose and 13% as likely to do so as fructose, which may explain why glucose is used as the primary metabolic fuel in humans.

A complication in medicine, or medical complication, is an unfavorable result of a disease, health condition, or treatment. Complications may adversely affect the prognosis, or outcome, of a disease. Complications generally involve a worsening in the severity of the disease or the development of new signs, symptoms, or pathological changes that may become widespread throughout the body and affect other organ systems. Thus, complications may lead to the development of new diseases resulting from previously existing diseases. Complications may also arise as a result of various treatments.

<span class="mw-page-title-main">Diabetic nephropathy</span> Chronic loss of kidney function

Diabetic nephropathy, also known as diabetic kidney disease, is the chronic loss of kidney function occurring in those with diabetes mellitus. Diabetic nephropathy is the leading causes of chronic kidney disease (CKD) and end-stage renal disease (ESRD) globally. The triad of protein leaking into the urine, rising blood pressure with hypertension and then falling renal function is common to many forms of CKD. Protein loss in the urine due to damage of the glomeruli may become massive, and cause a low serum albumin with resulting generalized body swelling (edema) so called nephrotic syndrome. Likewise, the estimated glomerular filtration rate (eGFR) may progressively fall from a normal of over 90 ml/min/1.73m2 to less than 15, at which point the patient is said to have end-stage renal disease. It usually is slowly progressive over years.

The term diabetes includes several different metabolic disorders that all, if left untreated, result in abnormally high concentrations of a sugar called glucose in the blood. Diabetes mellitus type 1 results when the pancreas no longer produces significant amounts of the hormone insulin, usually owing to the autoimmune destruction of the insulin-producing beta cells of the pancreas. Diabetes mellitus type 2, in contrast, is now thought to result from autoimmune attacks on the pancreas and/or insulin resistance. The pancreas of a person with type 2 diabetes may be producing normal or even abnormally large amounts of insulin. Other forms of diabetes mellitus, such as the various forms of maturity-onset diabetes of the young, may represent some combination of insufficient insulin production and insulin resistance. Some degree of insulin resistance may also be present in a person with type 1 diabetes.

A diabetic diet is a diet that is used by people with diabetes mellitus or high blood sugar to minimize symptoms and dangerous complications of long-term elevations in blood sugar.

<span class="mw-page-title-main">Prediabetes</span> Predisease state of hyperglycemia with high risk for diabetes

Prediabetes is a component of the metabolic syndrome and is characterized by elevated blood sugar levels that fall below the threshold to diagnose diabetes mellitus. It usually does not cause symptoms but people with prediabetes often have obesity, dyslipidemia with high triglycerides and/or low HDL cholesterol, and hypertension. It is also associated with increased risk for cardiovascular disease (CVD). Prediabetes is more accurately considered an early stage of diabetes as health complications associated with type 2 diabetes often occur before the diagnosis of diabetes.

<span class="mw-page-title-main">Diabetic cardiomyopathy</span> Medical condition

Diabetic cardiomyopathy is a disorder of the heart muscle in people with diabetes. It can lead to inability of the heart to circulate blood through the body effectively, a state known as heart failure(HF), with accumulation of fluid in the lungs or legs. Most heart failure in people with diabetes results from coronary artery disease, and diabetic cardiomyopathy is only said to exist if there is no coronary artery disease to explain the heart muscle disorder.

<span class="mw-page-title-main">Insulin (medication)</span> Use of insulin protein and analogs as medical treatment

As a medication, insulin is any pharmaceutical preparation of the protein hormone insulin that is used to treat high blood glucose. Such conditions include type 1 diabetes, type 2 diabetes, gestational diabetes, and complications of diabetes such as diabetic ketoacidosis and hyperosmolar hyperglycemic states. Insulin is also used along with glucose to treat hyperkalemia. Typically it is given by injection under the skin, but some forms may also be used by injection into a vein or muscle. There are various types of insulin, suitable for various time spans. The types are often all called insulin in the broad sense, although in a more precise sense, insulin is identical to the naturally occurring molecule whereas insulin analogues have slightly different molecules that allow for modified time of action. It is on the World Health Organization's List of Essential Medicines. In 2020, regular human insulin was the 307th most commonly prescribed medication in the United States, with more than 1 million prescriptions.

Complications of diabetes are secondary diseases that are a result of elevated blood glucose levels that occur in diabetic patients. These complications can be divided into two types: acute and chronic. Acute complications are complications that develop rapidly and can be exemplified as diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar state (HHS), lactic acidosis (LA), and hypoglycemia. Chronic complications develop over time and are generally classified in two categories: microvascular and macrovascular. Microvascular complications include neuropathy, nephropathy, and retinopathy; while cardiovascular disease, stroke, and peripheral vascular disease are included in the macrovascular complications.

<span class="mw-page-title-main">History of diabetes</span> Aspect of history

The condition known today as diabetes is thought to have been described in the Ebers Papyrus. Ayurvedic physicians first noted the sweet taste of diabetic urine, and called the condition madhumeha. The term diabetes traces back to Demetrius of Apamea. For a long time, the condition was described and treated in traditional Chinese medicine asxiāo kě. Physicians of the medieval Islamic world, including Avicenna, have also written on diabetes. Early accounts often referred to diabetes as a disease of the kidneys. In 1674, Thomas Willis suggested that diabetes may be a disease of the blood. Johann Peter Frank is credited with distinguishing diabetes mellitus and diabetes insipidus in 1794.

In recent years it has become apparent that the environment and underlying mechanisms affect gene expression and the genome outside of the central dogma of biology. It has been found that many epigenetic mechanisms are involved in the regulation and expression of genes such as DNA methylation and chromatin remodeling. These epigenetic mechanisms are believed to be a contributing factor to pathological diseases such as type 2 diabetes. An understanding of the epigenome of Diabetes patients may help to elucidate otherwise hidden causes of this disease.

Empagliflozin, sold under the brand name Jardiance, among others, is an antidiabetic medication used to improve glucose control in people with type 2 diabetes. It is not recommended for type 1 diabetes. It is taken by mouth.

<span class="mw-page-title-main">Diabetes</span> Group of endocrine diseases characterized by high blood sugar levels

Diabetes mellitus, often known simply as diabetes, is a group of common endocrine diseases characterized by sustained high blood sugar levels. Diabetes is due to either the pancreas not producing enough insulin, or the cells of the body becoming unresponsive to the hormone's effects. Classic symptoms include thirst, polyuria, weight loss, and blurred vision. If left untreated, the disease can lead to various health complications, including disorders of the cardiovascular system, eye, kidney, and nerves. Untreated or poorly treated diabetes accounts for approximately 1.5 million deaths every year.

Mladen Vranic, MD, DSc, O.C., O.Ont, FRSC, FRCP(C), FCAHS, Canadian Medical Hall of Fame[CMHF] April 3, 1930 – June 18, 2019, was a Croatian-born diabetes researcher, best known for his work in tracer methodology, exercise and stress in diabetes, the metabolic effects of hormonal interactions, glucagon physiology, extrapancreatic glucagon, the role of the direct and indirect metabolic effects of insulin and the prevention of hypoglycemia. Vranic was recognized by a number of national and international awards for his research contributions, mentoring and administration including the Orders of Canada (Officer) and Ontario.

<span class="mw-page-title-main">Daniel J. Drucker</span> Canadian endocrinologist (born 1956)

Daniel Joshua Drucker is a Canadian endocrinologist. A Fellow of the Royal Society, he is a professor of medicine at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto. He is known for his research into intestinal hormones and their use in the treatment of diabetes and other metabolic diseases.

<span class="mw-page-title-main">Diabetes in India</span>

India has an estimated 77 million people formally diagnosed with diabetes, which makes it the second most affected in the world, after China. Furthermore, 700,000 Indians died of diabetes, hyperglycemia, kidney disease or other complications of diabetes in 2020. One in six people (17%) in the world with diabetes is from India. The number is projected to grow by 2045 to become 134 million per the International Diabetes Federation.

Anne Peters is a endocrinologist, diabetes expert, and professor of clinical medicine at the Keck School of Medicine of USC. She runs diabetes centers in well-served Beverly Hills and under-resourced East Los Angeles. She teaches physicians and people with diabetes around the world how to better treat the condition, through lifestyle, medications and technology.

References

  1. 1 2 3 4 5 Blackman, Carolyn (2001-11-30). "Toronto doctor recognized for work on diabetes". The Canadian Jewish News. Retrieved 2020-01-01.
  2. 1 2 3 "Dr. Bernard Zinman | Sinai Health Foundation". Dr. Bernard Zinman | Sinai Health Foundation. Retrieved 2020-01-01.
  3. "Bernard Zinman". www.obstetricmed.utoronto.ca. Retrieved 2020-01-01.
  4. "Multiple Diabetes Injections Could Yield to Injections Just 3 Times a Week". MIKAELA CONLEY, ABC NEWS, 9 March 2011
  5. Edward Shorter. Partnership for Excellence: Medicine at the University of Toronto and Academic Hospitals . University of Toronto Press; 1 January 2013. ISBN   978-1-4426-4595-0. p. 227 and 642.
  6. "How the diabetes-linked 'thrifty gene' triumphed with prejudice over proof". The Globe and Mail, Carolyn Abraham, February 25, 2011
  7. "What would Frederick Banting think of ‘insulin tourism’?". Macleans, by Alanna Mitchell, Aug 13, 2019
  8. 1 2 3 WICKENS, BARBARA. "Old foe, new hope | Maclean's | JUNE 21, 1993". Maclean's | The Complete Archive. Retrieved 2020-01-01.
  9. "Blood sugar control tied to long-term brain health with type 1 diabetes". Reuters. 2018-10-05. Retrieved 2020-01-01.
  10. Nathan, David M.; Group, for the DCCT/EDIC Research (2014-01-01). "The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview". Diabetes Care. 37 (1): 9–16. doi: 10.2337/dc13-2112 . ISSN   0149-5992. PMID   24356592.
  11. "EMPA-REG: Insights From a Lead Investigator". Medscape, interview by Aus Alzaid, September 28, 2015
  12. "Lilly diabetes drug slashes deaths 32 pct in heart-risk patients". Reuters, September 17, 2015, Ransdell Pierson
  13. "Order of Canada: Stephen Harper, Donna Strickland, Xavier Dolan among new appointments" . Retrieved 2020-01-01.
  14. "U of T faculty, alumni and other members of university community named to Order of Canada". University of Toronto News. Retrieved 2020-01-01.
  15. General, Office of the Secretary to the Governor (2019-12-20). "Governor General Announces 120 New Appointments to the Order of Canada". The Governor General of Canada. Retrieved 2020-01-01.
  16. "Outstanding Achievement in Clinical Diabetes Research Award - Bernard Zinman, OC, MDCM, FRCPC, FACP | American Diabetes Association". professional.diabetes.org. Retrieved 2022-07-20.